The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: Clinical trial evidence and experience

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

The treatment of persistent asthma has been aided by the recent approval of new medications. The combined inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) powder inhaler fluticasone furoate (FF)/vilanterol trifenatate (VI) is one of these new agents, which was recently approved as a maintenance therapy for persistent asthma. This once-daily ICS/LABA inhaler has previously been approved and used in chronic obstructive pulmonary disease as a maintenance therapy. Both FF and VI individually have been shown to have efficacy in the treatment of persistent asthma; the combination of FF/VI at the dose of 100/25 Î1/4g daily improves trough peak expiratory flows and forced expiratory volume in 1 s. It also reduces the frequency of asthma exacerbations in patients with persistent asthma. The once-daily dosing is well tolerated, with limited clinically significant adverse events; the once-daily inhaled dosing regimen should also improve medication adherence. The data supporting the use of the FF/VI inhaler in persistent asthma are reviewed. The dry powder inhaler of FF/VI (100/25 Î1/4g) is an effective and well tolerated once-daily maintenance treatment for patients with persistent asthma.

Original languageEnglish (US)
Pages (from-to)43-56
Number of pages14
JournalTherapeutic Advances in Respiratory Disease
Volume10
Issue number1
DOIs
StatePublished - Feb 1 2016

Fingerprint

Asthma
Clinical Trials
Nebulizers and Vaporizers
Adrenal Cortex Hormones
Dry Powder Inhalers
Medication Adherence
Forced Expiratory Volume
Therapeutics
vilanterol
fluticasone furoate
Powders
Chronic Obstructive Pulmonary Disease

Keywords

  • combined inhaler
  • fluticasone furoate/vilanterol trifenatate
  • inhaled corticosteroid
  • long-acting β2 agonist
  • persistent asthma
  • powder inhaler

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology (medical)

Cite this

@article{fb273438ca3d4a34b44054950070b518,
title = "The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: Clinical trial evidence and experience",
abstract = "The treatment of persistent asthma has been aided by the recent approval of new medications. The combined inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) powder inhaler fluticasone furoate (FF)/vilanterol trifenatate (VI) is one of these new agents, which was recently approved as a maintenance therapy for persistent asthma. This once-daily ICS/LABA inhaler has previously been approved and used in chronic obstructive pulmonary disease as a maintenance therapy. Both FF and VI individually have been shown to have efficacy in the treatment of persistent asthma; the combination of FF/VI at the dose of 100/25 {\^I}1/4g daily improves trough peak expiratory flows and forced expiratory volume in 1 s. It also reduces the frequency of asthma exacerbations in patients with persistent asthma. The once-daily dosing is well tolerated, with limited clinically significant adverse events; the once-daily inhaled dosing regimen should also improve medication adherence. The data supporting the use of the FF/VI inhaler in persistent asthma are reviewed. The dry powder inhaler of FF/VI (100/25 {\^I}1/4g) is an effective and well tolerated once-daily maintenance treatment for patients with persistent asthma.",
keywords = "combined inhaler, fluticasone furoate/vilanterol trifenatate, inhaled corticosteroid, long-acting β2 agonist, persistent asthma, powder inhaler",
author = "Albertson, {Timothy E} and Richards, {John R} and Amir Zeki",
year = "2016",
month = "2",
day = "1",
doi = "10.1177/1753465815619136",
language = "English (US)",
volume = "10",
pages = "43--56",
journal = "Therapeutic Advances in Respiratory Disease",
issn = "1753-4658",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma

T2 - Clinical trial evidence and experience

AU - Albertson, Timothy E

AU - Richards, John R

AU - Zeki, Amir

PY - 2016/2/1

Y1 - 2016/2/1

N2 - The treatment of persistent asthma has been aided by the recent approval of new medications. The combined inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) powder inhaler fluticasone furoate (FF)/vilanterol trifenatate (VI) is one of these new agents, which was recently approved as a maintenance therapy for persistent asthma. This once-daily ICS/LABA inhaler has previously been approved and used in chronic obstructive pulmonary disease as a maintenance therapy. Both FF and VI individually have been shown to have efficacy in the treatment of persistent asthma; the combination of FF/VI at the dose of 100/25 Î1/4g daily improves trough peak expiratory flows and forced expiratory volume in 1 s. It also reduces the frequency of asthma exacerbations in patients with persistent asthma. The once-daily dosing is well tolerated, with limited clinically significant adverse events; the once-daily inhaled dosing regimen should also improve medication adherence. The data supporting the use of the FF/VI inhaler in persistent asthma are reviewed. The dry powder inhaler of FF/VI (100/25 Î1/4g) is an effective and well tolerated once-daily maintenance treatment for patients with persistent asthma.

AB - The treatment of persistent asthma has been aided by the recent approval of new medications. The combined inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) powder inhaler fluticasone furoate (FF)/vilanterol trifenatate (VI) is one of these new agents, which was recently approved as a maintenance therapy for persistent asthma. This once-daily ICS/LABA inhaler has previously been approved and used in chronic obstructive pulmonary disease as a maintenance therapy. Both FF and VI individually have been shown to have efficacy in the treatment of persistent asthma; the combination of FF/VI at the dose of 100/25 Î1/4g daily improves trough peak expiratory flows and forced expiratory volume in 1 s. It also reduces the frequency of asthma exacerbations in patients with persistent asthma. The once-daily dosing is well tolerated, with limited clinically significant adverse events; the once-daily inhaled dosing regimen should also improve medication adherence. The data supporting the use of the FF/VI inhaler in persistent asthma are reviewed. The dry powder inhaler of FF/VI (100/25 Î1/4g) is an effective and well tolerated once-daily maintenance treatment for patients with persistent asthma.

KW - combined inhaler

KW - fluticasone furoate/vilanterol trifenatate

KW - inhaled corticosteroid

KW - long-acting β2 agonist

KW - persistent asthma

KW - powder inhaler

UR - http://www.scopus.com/inward/record.url?scp=84957593209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957593209&partnerID=8YFLogxK

U2 - 10.1177/1753465815619136

DO - 10.1177/1753465815619136

M3 - Review article

C2 - 26668137

AN - SCOPUS:84957593209

VL - 10

SP - 43

EP - 56

JO - Therapeutic Advances in Respiratory Disease

JF - Therapeutic Advances in Respiratory Disease

SN - 1753-4658

IS - 1

ER -